Evidence map›Paper›PMID 42688812›Full record

ArticleChemical science2026

Modular assembly and property profiling of an expansive, shape-defined library of pentacyclic saturated N-heterocycles.

Elia Boschi, Dmitry Mazunin, Alex Mueller, Daniel Zimmerli, David Wechsler, Marc-Olivier Ebert, Christian Bartelmus, Martin Binder, Bjoern Wagner, Christian Weinmann and 3 more

Abstract read
In one paragraph

Article in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Elia BoschiLaboratory for Organic Chemistry, Department of Chemistry and Applied Biosciences, ETH Zürich Zürich 8093 Switzerland bode@org.chem.ethz.ch.ORCID https://orcid.org/0000-0002-1429-4949
Dmitry MazuninF. Hoffmann-La Roche Ltd, Pharma Research and Early Development pRED Innovation Center Basel Grenzacherstrasse 124 Basel CH-4070 Switzerland wolfgang.haap@roche.com.
Alex MuellerF. Hoffmann-La Roche Ltd, Pharma Research and Early Development pRED Innovation Center Basel Grenzacherstrasse 124 Basel CH-4070 Switzerland wolfgang.haap@roche.com.
Daniel ZimmerliF. Hoffmann-La Roche Ltd, Pharma Research and Early Development pRED Innovation Center Basel Grenzacherstrasse 124 Basel CH-4070 Switzerland wolfgang.haap@roche.com.
David WechslerF. Hoffmann-La Roche Ltd, Pharma Research and Early Development pRED Innovation Center Basel Grenzacherstrasse 124 Basel CH-4070 Switzerland wolfgang.haap@roche.com.
Marc-Olivier EbertLaboratory for Organic Chemistry, Department of Chemistry and Applied Biosciences, ETH Zürich Zürich 8093 Switzerland bode@org.chem.ethz.ch.ORCID https://orcid.org/0000-0003-1507-219X
Christian BartelmusF. Hoffmann-La Roche Ltd, Pharma Research and Early Development pRED Innovation Center Basel Grenzacherstrasse 124 Basel CH-4070 Switzerland wolfgang.haap@roche.com.
Martin BinderF. Hoffmann-La Roche Ltd, Pharma Research and Early Development pRED Innovation Center Basel Grenzacherstrasse 124 Basel CH-4070 Switzerland wolfgang.haap@roche.com.
Bjoern WagnerF. Hoffmann-La Roche Ltd, Pharma Research and Early Development pRED Innovation Center Basel Grenzacherstrasse 124 Basel CH-4070 Switzerland wolfgang.haap@roche.com.
Christian WeinmannF. Hoffmann-La Roche Ltd, Pharma Research and Early Development pRED Innovation Center Basel Grenzacherstrasse 124 Basel CH-4070 Switzerland wolfgang.haap@roche.com.ORCID https://orcid.org/0000-0002-4943-7970
Carsten KrollF. Hoffmann-La Roche Ltd, Pharma Research and Early Development pRED Innovation Center Basel Grenzacherstrasse 124 Basel CH-4070 Switzerland wolfgang.haap@roche.com.
Wolfgang HaapF. Hoffmann-La Roche Ltd, Pharma Research and Early Development pRED Innovation Center Basel Grenzacherstrasse 124 Basel CH-4070 Switzerland wolfgang.haap@roche.com.ORCID https://orcid.org/0000-0001-6845-2124
Jeffrey W BodeLaboratory for Organic Chemistry, Department of Chemistry and Applied Biosciences, ETH Zürich Zürich 8093 Switzerland bode@org.chem.ethz.ch.ORCID https://orcid.org/0000-0001-8394-8910

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small-molecule drug discovery is increasingly applied to targets historically classified as "undruggable", such as non-coding RNAs and biomolecular interactions. These complex interfaces demand ligands with greater three-dimensional complexity and preferred physicochemical profiles that are deficient in typical small molecule chemical libraries housed in large pharmaceutical companies or commercial suppliers. Inspired by the need for novel libraries that might hypothetically address these target classes, we report the design, iterative synthesis, and comprehensive property profiling of a novel chemical library of shape-defined, morpholine-containing pentacycles. Utilizing iterative Stannyl Amine Protocol (iSnAP) reagents, we divergently assembled rigid, 3D-diverse scaffolds that exhibit a chameleonic basic character at physiological pH, elegantly balancing aqueous solubility with membrane permeability. Computational analysis of the 2400-member virtual library confirmed that it occupies a distinct, three-dimensional chemical space. Furthermore, high-throughput experimental profiling of the synthesized compounds revealed promising drug-like properties, including broad aqueous solubility, metabolic stability, low cytochrome P450 inhibition, and tunable membrane permeability. Although no bioactivity has yet been discovered from this library, the compounds offer a robust chemical foundation for future evaluations in ligand screenings targeting emerging therapeutic modalities.

Identifiers

PMID42688812
PMCPMC13537041

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.